nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

03.05.2020 | Original Article – Clinical Oncology

Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China

verfasst von: Jian Zang, Man Xu, Chen Li, Lina Zhao, Shanuan Luo, Jianhua Wang, Mei Shi

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Although several trials have confirmed the treatment efficacy of induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) from endemic area of China, little is known about the best regime for induction chemotherapy in non-endemic region. This study compared the treatment effect of Gemcitabine and cisplatin (GP) versus docetaxel and cisplatin (TP) followed by concurrent chemoradiotherapy in locoregionally advanced NPC from non-endemic area of China.

Materials and methods

A total of 196 locoregionally advanced NPC patients were enrolled in this study, with 142 and 54 patients in TP and GP followed by concurrent chemoradiotherapy groups. The primary endpoint was treatment response of induction chemotherapy. The secondary endpoints included disease-free survival. The Kaplan–Meier method was used to evaluate the efficacy between treatment groups.

Results

The median follow-up time was 45.5 months (range: 6–60.5 months). During induction chemotherapy course, GP contributed higher treatment response rate than TP (68.1% vs. 47.1%, p = 0.007). Patients in GP group had better DFS and LRFS than those in TP group (3-year and 5-year DFS, 86.8% and 82.5% vs. 71.7% and 68%, p = 0.036; 3-year and 5-year LRFS, 96.2% and 96.2% vs. 90.5% and 82.8%, p = 0.03). No significant difference of adverse events was observed between two treatment groups in the whole course.

Conclusion

This study suggested that GP followed by CCRT was better than TP followed by CCRT in improving survival outcomes of locoregionally advanced NPC patients from non-endemic area of China.

Nur mit Berechtigung zugänglich

Chen Y et al (2008) Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys 71:1356–1364. https://doi.org/10.1016/j.ijrobp.2007.12.028 CrossRefPubMed

Chen X et al (2014) Concurrent chemoradiotherapy comparison of taxanes and platinum versus 5-fluorouracil and platinum in nasopharyngeal carcinoma treatment. Chin Med J 127:142–149PubMed

Cheung F, Chan O, Ng WT, Chan L, Lee A, Pang SW (2012) The prognostic value of histological typing in nasopharyngeal carcinoma. Oral Oncol 48:429–433. https://doi.org/10.1016/j.oraloncology.2011.11.017 CrossRefPubMed

Ghosh-Laskar S et al (2019) Taxane-based Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: Prospective Results from a Non-endemic Cohort. Clin Oncol. https://doi.org/10.1016/j.clon.2019.06.011(Royal College of Radiologists [Great Britain]) CrossRef

Han F et al (2012) Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy. Clin Oncol 24:569–576. https://doi.org/10.1016/j.clon.2011.11.010(Royal College of Radiologists [Great Britain]) CrossRef

He Y, Guo T, Wang J, Sun Y, Guan H, Wu S, Peng X (2019) Which induction chemotherapy regimen followed by cisplatin-based concurrent chemoradiotherapy is the best choice among PF, TP and TPF for locoregionally advanced nasopharyngeal carcinoma? Ann Transl Med 7:104. https://doi.org/10.21037/atm.2019.02.15 CrossRefPubMedPubMedCentral

Hua YJ et al (2012) Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy. Eur J Cancer (Oxford England: 1990) 48:3422–3428. https://doi.org/10.1016/j.ejca.2012.06.016 CrossRef

Hui EP et al (2009) Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 27:242–249. https://doi.org/10.1200/jco.2008.18.1545 CrossRefPubMed

Lee N et al (2009) Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 27:3684–3690. https://doi.org/10.1200/jco.2008.19.9109 CrossRefPubMedPubMedCentral

Liu T et al (2018) A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis. Cancer Manag Res 10:6237–6245. https://doi.org/10.2147/cmar.S186233 CrossRefPubMedPubMedCentral

Lokesh KN et al (2018) Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma in adults: Results from a nonendemic region. Indian J Cancer 55:257–260. https://doi.org/10.4103/ijc.IJC_115_18 CrossRefPubMed

Mi JL et al (2017) Chemotherapy regimens containing taxanes or fluorouracil in nasopharyngeal carcinoma: which better? Oral Oncol 74:34–39. https://doi.org/10.1016/j.oraloncology.2017.09.003 CrossRefPubMed

Ou D et al (2016) Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. Oral Oncol 62:114–121. https://doi.org/10.1016/j.oraloncology.2016.10.011 CrossRefPubMed

Pan JJ et al (2016) Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer 122:3307–3315. https://doi.org/10.1002/cncr.30198 CrossRefPubMedPubMedCentral

Peng H et al (2018) Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: a big-data intelligence platform-based analysis. Oral Oncol 79:40–46. https://doi.org/10.1016/j.oraloncology.2018.02.011 CrossRefPubMed

Sun X et al (2014) Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol 110:398–403. https://doi.org/10.1016/j.radonc.2013.10.020 CrossRefPubMed

Sun Y et al (2016) Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 17:1509–1520. https://doi.org/10.1016/s1470-2045(16)30410-7 CrossRefPubMed

Wang J et al (2012) Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study. Radiat Oncol 7:2. https://doi.org/10.1186/1748-717x-7-2 CrossRefPubMedPubMedCentral

Zang J et al (2016) Prognostic model of death and distant metastasis for nasopharyngeal carcinoma patients receiving 3DCRT/IMRT in nonendemic area of China. Medicine 95:e3794. https://doi.org/10.1097/md.0000000000003794 CrossRefPubMedPubMedCentral

Zang J et al (2018) Induction chemotherapy followed by concurrent chemoradiotherapy is benefit for advanced stage nasopharyngeal carcinoma with different nonkeratinizing carcinoma subtypes. Sci Rep 8:13318. https://doi.org/10.1038/s41598-018-31050-z CrossRefPubMedPubMedCentral

Zhang MX et al (2015) Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer (Oxford England: 1990) 51:2587–2595. https://doi.org/10.1016/j.ejca.2015.08.006 CrossRef

Zhang Y et al (2019) Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Eng J Med. https://doi.org/10.1056/NEJMoa1905287 CrossRef

Zhao LN et al (2012) Clinical outcome for nasopharyngeal carcinoma with predominantly WHO II histology treated with intensity-modulated radiation therapy in non-endemic region of China. Oral Oncol 48:864–869. https://doi.org/10.1016/j.oraloncology.2012.03.001 CrossRefPubMed

Zhao C et al (2019) Locoregional control and mild late toxicity after reducing target volumes and radiation doses in patients with locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy (IC) followed by concurrent chemoradiotherapy: 10-year results of a phase 2 study. Int J Radiat Oncol Biol Phys 104:836–844. https://doi.org/10.1016/j.ijrobp.2019.03.043 CrossRefPubMed

Zheng L, Liao W, Xu P, Li B, Wen H, Zhang S (2018) Tumor volume reduction after gemcitabine plus cisplatin induction chemotherapy in locally advanced nasopharyngeal cancer: comparison with paclitaxel and cisplatin regimens. Med Sci Monit 24:8001–8008. https://doi.org/10.12659/msm.909736 CrossRefPubMedPubMedCentral

Zhu J, Duan B, Shi H, Li Y, Ai P, Tian J, Chen N (2019) Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma. Oral Oncol 97:37–43. https://doi.org/10.1016/j.oraloncology.2019.08.001 CrossRefPubMed

Titel: Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China
verfasst von: Jian Zang
Man Xu
Chen Li
Lina Zhao
Shanuan Luo
Jianhua Wang
Mei Shi
Publikationsdatum: 03.05.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03229-3

Springer Medizin

Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China

Abstract

Purpose

Materials and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2020

Bone marrow adipocytes enhance osteolytic bone destruction by activating 1q21.3(S100A7/8/9-IL6R)-TLR4 pathway in lung cancer

Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes

Targeting glycolysis with 2-deoxy-d-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors

Recommendations on complementary and alternative medicine within S3 guidelines in oncology: systematic quality assessment of underlying methodology

PROLAPSE: survey about local prostate cancer relapse salvage treatment with external beam re-irradiation: results of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie